Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) EBT (2016 - 2025)

Historic EBT for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to -$1.9 million.

  • Cumberland Pharmaceuticals' EBT fell 2739.05% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year increase of 6868.1%. This contributed to the annual value of -$6.5 million for FY2024, which is 288.6% down from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' EBT stood at -$1.9 million, which was down 2739.05% from -$729536.0 recorded in Q2 2025.
  • Cumberland Pharmaceuticals' EBT's 5-year high stood at $1.3 million during Q1 2025, with a 5-year trough of -$6.3 million in Q4 2023.
  • Its 5-year average for EBT is -$1.3 million, with a median of -$1.4 million in 2022.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' EBT crashed by 115512.1% in 2024 and then skyrocketed by 16630.53% in 2025.
  • Cumberland Pharmaceuticals' EBT (Quarter) stood at -$4.4 million in 2021, then skyrocketed by 44.88% to -$2.4 million in 2022, then crashed by 160.29% to -$6.3 million in 2023, then surged by 68.8% to -$2.0 million in 2024, then rose by 0.78% to -$1.9 million in 2025.
  • Its EBT was -$1.9 million in Q3 2025, compared to -$729536.0 in Q2 2025 and $1.3 million in Q1 2025.